5 Biotechs With Cash Runways Into 2025

Published by
The Street

By Maxx Chatsko In drug development, cash is king, especially during a market correction. If you think tech stocks have it rough right now, sneak a peek at biotech stocks. The sector is in the midst of its most severe correction ever. Although it’s healthy to see excess squeezed out of valuations, that’s no consolation to investors who bought in during the peak last year. And the worst of the correction could be ahead. That may sound scary, but investors aren’t helpless. It helps to navigate volatility by focusing on fundamentals. Here’s how a back-to-the-basics approach and a focus on compani…

Read More

See also  Top Finance Trends For 2022

Leave a Reply